Subscribe To
IKT / Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference
Content Topics
Inhibikase
Therapeutics
Present
Phase
1b
Clinical
Data
Upcoming
Ad pd
Alzheimer s
Parkinson s
Diseases
Conference
Stock
IKT
IKT News
By PRNewsWire
August 22, 2023
Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders
BOSTON and ATLANTA , Aug. 22, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmace more_horizontal
By PRNewsWire
May 8, 2023
Inhibikase Therapeutics to Report First Quarter Financial Results on May 15, 2023
BOSTON and ATLANTA , May 8, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceuti more_horizontal
By PRNewsWire
April 21, 2023
Inhibikase Therapeutics to Present at the 2023 Planet MicroCap Showcase
BOSTON and ATLANTA , April 21, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmace more_horizontal
By PRNewsWire
March 23, 2023
Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023
BOSTON and ATLANTA , March 23, 2023 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmac more_horizontal
By InvestorPlace
January 26, 2023
Why Is Inhibikase Therapeutics (IKT) Stock Down 11% Today?
Inhibikase Therapeutics (NASDAQ: IKT ) stock is falling on Thursday after the company announced a registered direct offering and private placement. St more_horizontal
By Seeking Alpha
November 15, 2022
Inhibikase Therapeutics, Inc. (IKT) Q3 2022 Earnings Call Transcript
Inhibikase Therapeutics, Inc. (NASDAQ:IKT ) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Inv more_horizontal
By PRNewsWire
March 8, 2022
Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD™ Alzheimer's & Parkinson's Diseases Conference
BOSTON and ATLANTA, March 8, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company de more_horizontal